ArticleLeukemia2026

Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.

Noffar Bar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.